Limited expression of B-cell maturation antigen in acute myeloid leukemia - PubMed
6 hours ago
- #AML
- #BCMA
- #Immunotherapy
- B-cell maturation antigen (BCMA) was previously considered a target for T-cell-directed therapy in acute myeloid leukemia (AML) due to reported high expression.
- Independent research found limited BCMA expression in AML patient samples and cell lines, contradicting prior findings.
- The study identified non-specific binding of the anti-BCMA antibody clone 19F2 (BCMA-19F2) to AML cells via its non-antigen-binding fragment.
- Anti-BCMA CAR T-cell therapy showed minimal leukemic cell lysis, indicating limited efficacy in AML.
- The findings emphasize the importance of accurate antigen assessment for designing effective immunotherapies.